Table 1

Patients with COVID-19 characteristics

Demographics
 Female sex, n (%)80 (65.6)
 Caucasian ethnicity, n (%)98 (80.3)
 Age (mean±SD),58.3±16.3
Comorbidity, n (%)
 Hypertension48 (39.3)
 Obesity27 (23.6)
 Chronic pulmonary disease20 (16.4)
 Cardiovascular disease21 (17.2)
 Diabetes mellitus14 (11.5)
 Active smokers7 (5.6)
Treatment with ACE/ARB, n (%)34 (27.9)
Rheumatic diseases, n (%)
 RA41 (33.6)
 SpA24 (19.7)
 SLE13 (10.7)
 PsA13 (10.7)
 Miscellaneous*31 (25.4)
Duration of rheumatic disease (mean±SD), years12.2±9.3
Concomitant treatment, n (%)
Hydroxychloroquine 26 (21.3)
Glucocorticoids 48 (39.3)
 cDMARDs80 (65.6)
  Methotrexate54 (44.3)
  Sulfasalazine19 (15.6)
  Leflunomide13 (10.7)
  Azathioprine2 (1.6)
  Cyclophosphamide1 (0.8)
 bDMARDs/tsDMARDs42 (34.4)
  Anti-TNF28 (23.0)
  Rituximab7 (5.7)
  Abatacept3 (2.5)
  Tocilizumab1 (0.8)
  Sarilumab†
  Secukinumab0 (0.0)
  Tofacitinib1 (0.8)
  Baricitinib1 (0.8)
Symptoms, n (%)
 Dry, non-productive cough84 (74.3)
 Fever74 (64.3)
 Dyspnoea59 (50.0)
 Arthromyalgia42 (36.5)
 Anosmia/ageusia41 (37.5)
 Nausea/vomiting39 (33.9)
Respiratory insufficiency, n (%)54 (52.5)
Non-invasive oxygen supplementation, n (%)50 (41.0)
Pneumonia, n (%)67 (54.9)
Time from disease onset to hospital admission, days (median, IQR)7.2 (4.1–10.5)
Hospital admission, n (%)69 (56.6)
ICU admission, n (%)6 (4.9)
Time of hospital admission, days (median, IQR)8.0 (5.0–15.2)
COVID-19 specific treatment, n (%)
 Hydroxychloroquine76 (62.3)
 Azithromycin50 (41.0)
 Glucocorticoids8 (6.6)
 Lopinavir/ritonavir6 (4.9)
 Anti-IL66 (4.9)
 Anti-IL12 (1.6)
 IVIg3 (2.5)
Recovered patients, n (%)106 (87.6)
Exitus, n (%)14 (11.5)
  • *See online supplementary table S1.

  • †One patient on double blind clinical trial with sarilumab versus placebo.

  • ARB, angiotensin-receptor blocker; bDMARDs, biological disease-modifying antirheumatic drugs; cDMARDs, conventional synthetic disease-modifying antirheumatic drugs; ICU, intensive care units; IL, interleukin; IVIg, intravenous immunoglobulins; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SpA, spondyloarthritis; TNF, tumour necrosis factor; tsDMARDs, targeted synthetic disease-modifying antirheumatic drugs.